论文部分内容阅读
为了观察吉西他滨联合卡培他滨治疗晚期肝癌的临床疗效及不良反应,选择无法手术及介入治疗的晚期原发性肝癌患者26例,给予吉西他滨1000mg/m2,持续静脉滴入30min,d1、d8;卡培他滨1000mg/m2,口服,2次/d,d1～d14,21d为1个周期,入组的每例患者至少接受2个周期的治疗。结果PR11例(42.3%),NC6例(23.1%),PD9例(34.6%),客观有效率(PR+CR)为42.3%(11/26);疾病控制率(PR+CR+SD)为65.4%(17/26)。不良反应主要有血液学毒性(主要为中性粒细胞减少和血小板减少)和手足综合征,多为1～2度,耐受性良好。中位生存期(MST)6.8个月,1年生存率38.5%。初步研究结果提示,吉西他滨联合卡培他滨治疗晚期肝癌的疗效及患者依从性好,用药方便,费用相对低廉,值得临床进一步研究。
In order to observe the clinical efficacy and adverse reactions of gemcitabine combined with capecitabine in the treatment of advanced liver cancer, 26 patients with advanced primary hepatic cancer who can not be operated and interventional treatment were given gemcitabine 1000mg / m2, continuous intravenous infusion for 30min, d1, d8; Capecitabine 1000mg / m2, orally, 2 times / d, d1 ~ d14, 21d for a cycle, each patient enrolled in at least two cycles of treatment. Results PR 11 cases (42.3%), NC6 cases (23.1%), PD9 cases (34.6%) and objective response rate (PR + CR) were 42.3% (11/26) 65.4% (17/26). Adverse reactions are mainly hematological toxicity (mainly neutropenia and thrombocytopenia) and hand-foot syndrome, mostly 1 to 2 degrees, well tolerated. Median survival (MST) 6.8 months, 1-year survival rate of 38.5%. Preliminary results suggest that gemcitabine combined with capecitabine in the treatment of advanced liver cancer and compliance of patients with good, convenient medication, the cost is relatively low, it is worth further clinical study.